Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.

Lau YF, Tang LH, Chien Lye D, Ooi EE, Leo YS.

Hum Vaccin Immunother. 2017 Mar 4;13(3):551-560. doi: 10.1080/21645515.2016.1246636. Epub 2017 Feb 17.

PMID:
28277090
2.

Immunogenicity and safety of intradermal influenza vaccine in immunocompromized patients: a meta-analysis of randomized controlled trials.

Pileggi C, Lotito F, Bianco A, Nobile CG, Pavia M.

BMC Infect Dis. 2015 Oct 14;15:427. doi: 10.1186/s12879-015-1161-z.

3.

Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics.

Pediatr Infect Dis J. 2013 Nov;32 Suppl 2:i-KK4. doi: 10.1097/01.inf.0000437856.09540.11. No abstract available.

4.

Influenza vaccination in HIV-positive subjects: latest evidence and future perspective.

Ceravolo A, Orsi A, Parodi V, Ansaldi F.

J Prev Med Hyg. 2013 Mar;54(1):1-10. Review.

5.

Immune activation and viral replication after vaccination with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy.

Onlamoon N, Unpol P, Boonchan M, Sukapirom K, Wittawatmongkol O, Chokephaibulkit K, Ammaranond P, Pattanapanyasat K.

Dis Markers. 2013;35(4):221-7. doi: 10.1155/2013/276547. Epub 2013 Sep 5.

6.

Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.

Kelly D, Burt K, Missaghi B, Barrett L, Keynan Y, Fowke K, Grant M.

BMC Immunol. 2012 Aug 31;13:49. doi: 10.1186/1471-2172-13-49.

7.

Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Agrati C, Gioia C, Castilletti C, Lapa D, Berno G, Puro V, Carletti F, Cimini E, Nisii C, Castellino F, Martini F, Capobianchi MR.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1606-16. doi: 10.1089/AID.2011.0371. Epub 2012 May 8.

8.

Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort.

Steffens B, Kümmerle T, Koch S, Birtel A, Schwarze-Zander C, Emmelkamp J, Kern WV, Hertenstein C, Wyen C, Lehmann C, Cornely OA, Rockstroh J, Fätkenheuer G.

Eur J Med Res. 2011 Jul 25;16(7):289-94.

9.

Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.

Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, Shafran S, Zubyk W, Singer J, Halperin S, Walmsley S; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group.

PLoS One. 2011 Mar 25;6(3):e17758. doi: 10.1371/journal.pone.0017758.

10.

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults.

Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, Defang G, Bai Y, Iverson E, Lalani T, Whitman T, Blair PJ, Brandt C, Macalino G, Burgess T.

Clin Infect Dis. 2011 Jan 1;52(1):138-46. doi: 10.1093/cid/ciq019. Epub 2010 Dec 7.

11.

Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults.

Kiberd M, Cooper C, Slaunwhite J, Halperin B, Haase D, McNeil S.

Can J Infect Dis Med Microbiol. 2009 Winter;20(4):e124-9.

12.

Effect of treating co-infections on HIV-1 viral load: a systematic review.

Modjarrad K, Vermund SH.

Lancet Infect Dis. 2010 Jul;10(7):455-63. doi: 10.1016/S1473-3099(10)70093-1. Review.

13.

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Kunisaki KM, Janoff EN.

Lancet Infect Dis. 2009 Aug;9(8):493-504. doi: 10.1016/S1473-3099(09)70175-6. Review.

14.

A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults.

Cooper C, Hutton B, Fergusson D, Mills E, Klein MB, Boivin G, Halperin S.

Can J Infect Dis Med Microbiol. 2008 Nov;19(6):419-23.

15.

A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.

Madan RP, Tan M, Fernandez-Sesma A, Moran TM, Emre S, Campbell A, Herold BC.

Clin Infect Dis. 2008 Mar 1;46(5):712-8. doi: 10.1086/527391.

16.

Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults.

Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, Renzoni A, Fabbri P, Ferrera A, Parodi A, Bruzzone B, Gabutti G, Podda A, Del Giudice G, Fragapane E, Indiveri F, Crovari P, Gasparini R.

Clin Vaccine Immunol. 2008 Feb;15(2):253-9. Epub 2007 Nov 14.

17.

Supplemental Content

Support Center